Literature DB >> 28278702

Krüppel-like factor 4 contributes to the pathogenesis of mantle cell lymphoma.

Xin-Yu Li1, Ling-Yun Geng1, Xiang-Xiang Zhou1, Na Wei1, Xiao-Sheng Fang1, Ying Li1, Xin Wang1.   

Abstract

Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) with poor prognosis. Krüppel-like factor 4 (KLF4) has been reported as a bi-regulator in malignancies, but little is known about its role in MCL. Here, we showed that KLF4 was downregulated in three MCL cell lines and lymph nodes from MCL patients, which resulted in a negative prognosis. We also found that the regulation of KLF4 could inhibit the proliferation and induce apoptosis of Jeko-1 cells. The lentivirally over-expressed KLF4 protein was found bind to β-catenin and could inhibit downstream molecules such as cyclinD1 and c-Myc. Furthermore, 5-azacytidine could decrease the expression of methyltransferase-1 (DNMT-1) and restore the KLF4 expression in MCL cell lines, indicating that methylation might play an important role in the downregulation of KLF4. KLF4 may be a potential therapeutic target as a tumor suppressor in MCL.

Entities:  

Keywords:  5-azacytidine; KLF4; Mantle cell lymphoma; Wnt/β-catenin pathway; tumor suppressor

Mesh:

Substances:

Year:  2017        PMID: 28278702     DOI: 10.1080/10428194.2017.1292354

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.

Authors:  Yan Xiu; Qianze Dong; Lin Fu; Aaron Bossler; Xiaobing Tang; Brendan Boyce; Nicholas Borcherding; Mariah Leidinger; José Luis Sardina; Hai-Hui Xue; Qingchang Li; Andrew Feldman; Iannis Aifantis; Francesco Boccalatte; Lili Wang; Meiling Jin; Joseph Khoury; Wei Wang; Shimin Hu; Youzhong Yuan; Endi Wang; Ji Yuan; Siegfried Janz; John Colgan; Hasem Habelhah; Thomas Waldschmidt; Markus Müschen; Adam Bagg; Benjamin Darbro; Chen Zhao
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

2.  Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.

Authors:  Wen-Hsin Liu; Paulina Mrozek-Gorska; Anna-Katharina Wirth; Tobias Herold; Larissa Schwarzkopf; Dagmar Pich; Kerstin Völse; M Camila Melo-Narváez; Michela Carlet; Wolfgang Hammerschmidt; Irmela Jeremias
Journal:  Biomark Res       Date:  2020-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.